




PHARMACEUTICAL 2019

Altimmune Inc.
Rank 132 of 363





RealRate

PHARMACEUTICAL 2019

Altimune Inc.
Rank 132 of 363



The relative strengths and weaknesses of Altimune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimune Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Altimune Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 143%, being 106% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	39,372
Cost of Goods Sold	0
Intangible Assets	13,852
Liabilities, Current	4,527
Liabilities, Non-Current	0
Other Assets	184
Other Compr. Net Income	-463
Other Expenses	18,791
Other Liabilities	1,911
Other Net Income	-2,487
Other Revenues	10,331
Property and Equipment	1,343
Research and Development	18,459
Selling, General and Administrative Expense	9,766

Output Variable	Value in 1000 USD
Assets	54,751
Liabilities	6,438
Expenses	47,016
Revenues	10,331
Stockholders Equity	48,313
Net Income	-39,171
Comprehensive Net Income	-39,403
Economic Capital Ratio	143%